Leukemia Research Foundation

05/27/2026

Buddy the Blood Drop and runners and walkers from all over the Chicagoland area will join us this Saturday, May 30 at Montrose Harbor for the 32nd ABC7 ABC 7 Gibbons Run and Walk. Register now or register onsite, and get ready to Lace Up For Leukemia! https://bit.ly/4dPvDHG

Back again this year, Buddy the Blood Drop.
Find him. Snap a pic.

05/27/2026

This month marks 25 years since a revolutionary drug, Gleevec, was approved by the FDA, transforming chronic myeloid leukemia (CML) from a fatal diagnosis to a highly manageable condition.

Contributing to this drug’s discovery was the work of renowned University of Chicago researcher Dr. Janet Rowley. Dr. Rowley had received two grants from the Leukemia Research Foundation to fund her CML research. She discovered a recurring chromosome translocation – an abnormality when a chromosome breaks and a fragmented piece reattaches to another chromosome - which resulted in the Philadelphia chromosome seen in CML.

This historic finding helped spur the development and ultimate discovery of Gleevec, which changed the CML survival rate from 3-to-5 years into a normal life expectancy. Learn more about our research grant program: https://bit.ly/4tSRTX3

05/22/2026

This month marks 25 years since a revolutionary drug, Gleevec, was approved by the FDA, transforming chronic myeloid leukemia (CML) from a fatal diagnosis to a highly manageable condition.

Contributing to this drug’s discovery was the work of renowned University of Chicago researcher Dr. Janet Rowley. Dr. Rowley had received two grants from the Leukemia Research Foundation to fund her CML research. She discovered a recurring chromosome translocation – an abnormality when a chromosome breaks and a fragmented piece reattaches to another chromosome - which resulted in the Philadelphia chromosome seen in CML.

This historic finding helped spur the development and ultimate discovery of Gleevec, which changed the CML survival rate from 3-to-5 years into a normal life expectancy. Learn more about our research grant program: https://bit.ly/4tSRTX3

05/21/2026

In a study published in the journal Science Translational Medicine, a team of scientists from The Jackson Laboratory revealed not only a potential new way to treat acute myeloid leukemia (AML) without harsh chemotherapy, but also a promising strategy to study more gene-silencing mechanisms in other diseases.

The research, led by Eric Wang, PhD, a 2024 Leukemia Research Foundation New Investigator Research Grant (NIRG) recipient, was funded in part by the Foundation. In addition, two former NIRG recipients also contributed to this study: Hussein Abbas, MD, PhD (2022) and Iannis Aifantis, PhD (2003).

Learn more about the study: https://bit.ly/4eV4ncS

05/06/2026

Happy National Nurses Week! Nurses play a key part in any treatment plan. This short video clip from our recent webinar, "Your Care Team", features Dawn Urbanovsky, RN, BSN, OCN, a treatment nurse navigator from MD Anderson, who discusses the role of treatment nurse navigators and how they can help patients set up second opinions, as she does at MD Anderson. Watch video clip: https://bit.ly/4tJyOY5

04/29/2026

Join us, May 12 when Dr. Uma Borate from The Ohio State Comprehensive Cancer Center shares the latest information about clinical trials. Find out how they work, what factors to consider, and who is eligible for them. Register now! https://bit.ly/48wEX14

04/20/2026

We support others around the world in recognizing AML Awareness Day. Acute myeloid leukemia (AML) is a rare aggressive blood and bone marrow cancer. Peer support for patients and caregivers can be effective in providing emotional and social aid during their AML journey. For more information on peer support and other patient and family support options, visit https://leukemiarf.org/patients

04/20/2026

📣 Breaking News!
CALL FOR APPLICATIONS!
ESH is proud to announce the 7th International John Goldman Research Award !
Fund your research project with a focus on MRD in CML and MPN related diseases.
To proceed and for more information → bit.ly/35DnsOU
The deadline is on May 31st, 2026

British Society for Haematology Sociedade Portuguesa de Hematologia

04/17/2026

Join us at Montrose Harbor on May 30!

04/14/2026

Immunotherapy offers new treatment possibilities for leukemia patients beyond traditional chemotherapy. Join our webinar on April 27 as Dr. Gregory Behbehani from The Ohio State University and Dr. Adam Kittai from New York University Grossman Long Island School of Medicine explore current options and upcoming advances, helping you better engage in discussions with your care team. Register now: https://bit.ly/3NH1ill

There are now multiple treatment options for acute and chronic leukemia patients that are approved or in development in the category of “immunotherapy.” What is immunotherapy and how is it different from chemotherapy and other available treatments? Get your questions answered by experts in this ...